---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-24-000024"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:58:33.823519+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xeris reports Q4 total revenue $44.4M (+34% YoY); refinances debt with $200M Hayfin facility

## Summary
- Q4 total revenue $44.4M, +34% YoY; full-year 2023 revenue $163.9M, +49% YoY.
- Net loss in Q4 $13.4M ($0.10 loss per share); year-end cash $72.5M.
- FY2024 guidance: total net revenue $170M-$200M; year-end cash $55M-$75M.
- Refinanced existing $150M Hayfin loan with new $200M term loan; additional $15.2M available to redeem 2025 notes.
- New loan bears 6.95% + SOFR (floor 2%) interest; maturity March 2029; reduces borrowing cost by 2.05%.

## SEC filing metadata
- accession: 0001867096-24-000024
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/0001867096-24-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/xers-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-24-000024
- JSON: https://secwatch.observer/filing/0001867096-24-000024.json
- Plain text: https://secwatch.observer/filing/0001867096-24-000024.txt

## Key facts
- Debt Financings
  Xeris Biopharma Holdings, Inc. incurred term loan of $200.0 million in term loans (the “Tranche 1 Loans”) with Hayfin Services LLP at (i) 6.95% (or 5.95% if the replacement rate is in effect) plus (ii) the greater maturing March 5, 2029.
  - Instrument: term loan
  - Principal: $200.0 million in term loans (the “Tranche 1 Loans”)
  - Counterparty: Hayfin Services LLP
  - Rate: (i) 6.95% (or 5.95% if the replacement rate is in effect) plus (ii) the greater
  - Maturity: March 5, 2029
  - Event: incurrence
  source text: The Amended and Restated Credit Agreement provided for the New Lenders to extend $200.0 million in term loans (the “Tranche 1 Loans”) to Xeris Pharma on the closing date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/0001867096-24-000024-index.htm
- Debt Financings
  Xeris Biopharma Holdings, Inc. incurred term loan of $15.2 million in additional term loans (the “Tranche 2 Loans”) with Hayfin Services LLP maturing March 5, 2029.
  - Instrument: term loan
  - Principal: $15.2 million in additional term loans (the “Tranche 2 Loans”)
  - Counterparty: Hayfin Services LLP
  - Maturity: March 5, 2029
  - Event: incurrence
  source text: $15.2 million in additional term loans (the “Tranche 2 Loans” and, together with the Tranche 1 Loans, the “2029 Loans”) on any date after the closing date and through July 15, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/0001867096-24-000024-index.htm
- Earnings Releases
  Xeris Biopharma Holdings, Inc. reported financial results for the three and twelve months ended December 31, 2023.
  - Period: the three and twelve months ended December 31, 2023
  - Result: reported results
  source text: On March 6, 2024, the Company issued a press release containing information about the Company's results of operations and business highlights for the three and twelve months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/0001867096-24-000024-index.htm
- Material Agreements
  Xeris Biopharma Holdings, Inc. entered into Amended and Restated Credit Agreement with Hayfin Services LLP, as administrative agent valued at $200.0 million in term loans (effective 2024-03-05).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Hayfin Services LLP, as administrative agent
  - Value: $200.0 million in term loans
  - Effective: 2024-03-05
  source text: On March 5, 2024, Xeris Biopharma Holdings, Inc. (the “Company”), Xeris Pharmaceuticals, Inc. (“Xeris Pharma”) and certain subsidiary guarantors of the Company entered into an Amended and Restated Credit Agreement and Guaranty (the “Amended and Restated Credit Agreement”) with the lenders from time to time parties thereto (the “New Lenders”) and Hayfin Services LLP, as administrative agent for the New Lenders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/0001867096-24-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.